KHUSHBU ANIRUDHDHA CHANDARANA
Allopathic & Osteopathic Physicians|Internal Medicine|Endocrinology, Diabetes & Metabolism CARY, NC NPI 1609084151
Browse related groups: Allopathic & Osteopathic Physicians|Internal Medicine|Endocrinology, Diabetes & Metabolism NC Novo Nordisk AS All categories
General Payments — all program years on this page
$2,585.36
- Category: General Payments
- Program years: PY2018–2024
- Record count: 155
- As of (CMS publication): 2026-01-23
Latest program year (PY2024): $144.70 across 8 records · disputed records: 0
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How this figure is calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
Latest program year (PY2024) · sorted by reported total.
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $144.70 | 8 |
By paying entity
Latest program year (PY2024) · sorted by reported total.
| Paying entity | Amount | Records |
|---|---|---|
| Novo Nordisk AS | $52.05 | 3 |
| Abbott Laboratories | $39.60 | 2 |
| Medtronic, Inc. | $21.97 | 1 |
| Takeda Pharmaceuticals U.S.A., Inc. | $17.53 | 1 |
| IBSA Pharma Inc. | $13.55 | 1 |
By program year
Records — PY2024 (8)
| Record ID | Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Source |
|---|---|---|---|---|---|---|---|
| 1096866711 | Novo Nordisk Inc | $17.05 | 03/28/2024 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
| 1096992637 | Novo Nordisk Inc | $15.09 | 01/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
| 1097512910 | Novo Nordisk Inc | $19.91 | 06/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
| 1119397320 | Medtronic, Inc. | $21.97 | 03/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
| 1125148106 | Abbott Laboratories | $18.54 | 02/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
| 1125148108 | Abbott Laboratories | $21.06 | 07/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
| 1137506794 | Takeda Pharmaceuticals U.S.A., Inc. | $17.53 | 02/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
| 1142978921 | IBSA Pharma Inc. | $13.55 | 01/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
Provenance & corrections
- Dataset: CMS Open Payments — General Payments
- Source: CMS Open Payments dataset (bulk file)
- Publisher of source data: Centers for Medicare & Medicaid Services
- Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.